Physician profile
Nancy J Eisen
NPI 1629136387
$2,631.20
in general payments reported to CMS, 2019-2025
22 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $661 · 2021: $500 · 2022: $70.07 · 2023: $146 · 2024: $218 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $573.16 | 2019-2025 | Wegovy |
| Glaxosmithkline, LLC. | $513.13 | 2019-2025 | Bexsero, Pediarix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.90 | 2019-2021 | |
| Lilly USA, LLC | $214.18 | 2019-2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $212.56 | 2019-2021 | |
| Allergan, INC. | $135.99 | 2019-2020 | |
| Pfizer INC. | $129.89 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $94.88 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Gilead Sciences, INC. | $75.10 | 2019-2020 | |
| Amarin Pharma, INC. | $59.33 | 2019-2021 | |
| Abbvie INC. | $52.02 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $44.88 | 2020-2021 | |
| Exact Sciences Corporation | $41.03 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $41.02 | 2019 | |
| Genentech USA, INC. | $40.49 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.10 | 2021 | |
| Abbott Laboratories | $32.95 | 2023-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $27.19 | 2021-2022 | |
| Dynavax Technologies Corporation | $26.75 | 2021-2025 | Heplisav-B |
| Astellas Pharma US INC | $16.52 | 2021 | |
| Boston Scientific Corporation | $14.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Eisen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.